Mirum Pharmaceuticals, Inc.

NASDAQ:MIRM

Biotechnology

Healthcare
$92.49 +3.81%

+$3.89 today

Market cap
$6.04B
Beta
0.51
P/E (TTM)
-7.8
EPS (TTM)
-$13.57
52W Low $47.89High $114.99

Volume 0.50M

Average 0.95M

MIRM Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Mirum Pharmaceuticals, Inc.NASDAQ: MIRM

Gross Margin · Q2 FY2026 · quarter ended Jun 2026

Gross margin widens to 82.8%

Gross margin was 82.8% in Q2 FY2026, up 1.1 pp from a year earlier. On a trailing-twelve-month basis it was 81.7%, up 2.7 pp year over year. Over 3 fiscal years it narrowed by 3.2 pp.

Context

  • Gross margin widened in 2 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
82.8%+0.8 pp QoQ
Last fiscal yearDec 2025
80.7%+4.9 pp YoY
LTMJun 2026
81.7%+2.7 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+1.1 pp——
1 year+4.9 pp——
3 years-3.2 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
80.7%
Year-over-year change
+4.9pp

Gross Margin vs competitors

How MIRM compares with its peers on the latest reported figures

  • MIRM's LTM Jun 2026 gross margin of 81.7% is the 6th highest of the 8 companies compared; the peer median is 83.6%.
  • Its year-over-year change of +2.7 pp is the highest of 8, against a peer median of -4.8 pp.
  • Over three fiscal years its change of -3.2 pp compares with a peer median of -5.8 pp.
MIRM Competitors Peer median
Gross Margin for MIRM and competitors
Company Period LTM level YoY 3-year change
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 202698.3% -1.7 pp-7.0 pp
MDGLMadrigal Pharmaceuticals, Inc.LTM Jun 202691.5% -4.8 pp—
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 202691.2% -8.8 pp-4.5 pp
RAREUltragenyx Pharmaceutical Inc.LTM Mar 202683.6% -1.6 pp-8.4 pp
AGIOAgios Pharmaceuticals, Inc.LTM Mar 202682.1% +2.3 pp-9.4 pp
MIRMMirum Pharmaceuticals, Inc.LTM Jun 202681.7% +2.7 pp-3.2 pp
TVTXTravere Therapeutics, Inc.LTM Sep 202660.7% -37.0 pp+1.9 pp
ALTAltimmune, Inc.LTM Mar 2026-41519.4% -41619.4 pp+0.0 pp
Peer median (excluding MIRM) 83.6%-4.8 pp-5.8 pp

Competitors are the stored peer set for MIRM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue19.14M77.06M186.37M336.89M521.31M
Cost of Revenue1.9M12.37M47.04M81.64M100.58M
Gross Profit17.24M64.69M139.34M255.25M420.73M
Gross Margin90.1%83.9%74.8%75.8%80.7%
Research & Development131.43M106.84M102.61M140.63M186.18M
Selling, General & Admin59.22M89.07M145.88M202.22M257.03M
Operating Expenses190.65M195.91M248.49M342.85M443.21M
Depreciation & Amortization975K3.24M10.83M23.63M24.24M
EBITDA(65.39M)(122.85M)(136.49M)(48.97M)17.21M
EBITDA Margin-341.7%-159.4%-73.2%-14.5%3.3%
Operating Income(173.41M)(131.22M)(109.15M)(87.61M)(22.14M)
Operating Margin-906.1%-170.3%-58.6%-26.0%-4.2%
Interest Income366K3.86M13.74M13.79M12.73M
Interest Expense17.59M15.98M15.11M14.31M14.39M
Other Income / Expenses89.46M(10.85M)(53.27M)694K709K
Income Before Tax(83.95M)(142.07M)(162.42M)(86.91M)(21.43M)
Pre-Tax Margin-438.7%-184.4%-87.1%-25.8%-4.1%
Income Tax Expense37K(6.41M)991K1.03M1.94M
Net Income(83.99M)(135.67M)(163.42M)(87.94M)(23.36M)
Net Margin-438.9%-176.0%-87.7%-26.1%-4.5%
EPS (Basic)(2.77)(4.01)(4.00)(1.85)(0.47)
EPS (Diluted)(2.77)(4.02)(4.00)(1.85)(0.47)
Weighted Avg Shares30.32M33.84M40.89M47.52M50.2M
Weighted Avg Shares (Diluted)30.32M33.98M40.89M47.52M50.2M

Mirum Pharmaceuticals, Inc.

NASDAQ:MIRM

Intrinsic Alpha fair value

Locked

Current Price

$92.49

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.